CJC-1295 + Ipamorelin: The Growth Hormone Peptide Stack Explained

The CJC-1295 and Ipamorelin combination is the most widely prescribed growth hormone peptide stack in clinical anti-aging and optimization settings. These two peptides work through different but complementary pathways to increase your body's own production of growth hormone (GH), rather than introducing synthetic GH directly. That distinction matters: you get a more physiological pulse pattern, fewer side effects, and a lower risk profile compared to exogenous HGH.[1]

This guide breaks down how each peptide works individually, why combining them produces a stronger effect than either one alone, what the dosing protocols look like, what you can realistically expect, and where the evidence stands. If you are new to peptides, start there first, then come back here for the specifics.

What Is the CJC-1295 + Ipamorelin Stack?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to your pituitary gland to produce growth hormone. Ipamorelin is a growth hormone secretagogue (GHS), a separate class of peptide that mimics ghrelin and triggers GH release through the ghrelin receptor.[3] When you combine both, you are pressing two different buttons on the same system at the same time.

Your pituitary gland releases growth hormone in pulses, not as a steady stream. The largest pulse happens during deep sleep, with smaller pulses throughout the day.[7] This pulsatile pattern is important because continuous GH elevation (like you get with synthetic HGH injections) can lead to receptor desensitization and side effects. The CJC-1295/Ipamorelin stack amplifies your natural pulses rather than overriding them, which is a core reason clinicians prefer it over direct GH replacement.

How CJC-1295 Works

CJC-1295 belongs to the GHRH analog family. Your hypothalamus naturally produces GHRH in short bursts, each lasting only a few minutes before enzymes break it down. CJC-1295 was designed to resist that enzymatic breakdown, giving your pituitary a longer, stronger signal to release growth hormone.[4]

There are two forms you will encounter. The first is CJC-1295 without DAC, also called Modified GRF (1-29) or Mod GRF. This version has a half-life of roughly 30 minutes and produces a sharp GH pulse. The second is CJC-1295 with DAC (Drug Affinity Complex), which binds to albumin in your blood and extends the half-life to 6-8 days.[1] The DAC version creates a more sustained GH elevation rather than a pulse, which is closer to how exogenous HGH works, and some clinicians prefer the non-DAC form for that reason.

In a 2006 clinical trial published in the Journal of Clinical Endocrinology and Metabolism, CJC-1295 (with DAC) increased mean GH levels by 2-10 fold and IGF-1 levels by 1.5-3 fold after a single injection, with effects lasting 6-14 days. The researchers noted that these increases were dose-dependent, with 30 mcg/kg and 60 mcg/kg producing the most significant elevations.[1]

CJC-1295 Without DAC vs. With DAC

Most clinical protocols that combine CJC-1295 with Ipamorelin use the non-DAC version (Mod GRF 1-29) because it preserves the natural pulsatile release pattern. The rest of this guide assumes the non-DAC form unless otherwise noted.

How Ipamorelin Works

Ipamorelin is a pentapeptide (five amino acids) that acts as a selective growth hormone secretagogue. It binds to the ghrelin receptor (GHS-R1a) on your pituitary somatotroph cells, triggering a burst of growth hormone release.[3] What makes Ipamorelin notable compared to older secretagogues like GHRP-6 or GHRP-2 is its selectivity: it stimulates GH release without significantly increasing cortisol, prolactin, or appetite.

That selectivity was first documented in a 1998 study published in the European Journal of Endocrinology, where Raun et al. demonstrated that Ipamorelin released GH with potency comparable to GHRP-6 but did not affect ACTH (adrenocorticotropic hormone) or cortisol at GH-releasing doses.[3] This matters because cortisol elevation is a known side effect of other secretagogues, and it directly opposes many of the benefits you are trying to get from increased GH output.

Ipamorelin also operates through a dose-dependent ceiling effect. Your pituitary can only release so much GH per pulse, and once you hit that saturation point, adding more Ipamorelin does not push GH higher. This built-in cap is part of what gives it a favorable safety profile compared to direct HGH injections, where dosing beyond physiological ranges is straightforward and carries real consequences (joint swelling, insulin resistance, organ growth).

Why Stack Them Together?

The rationale for combining CJC-1295 and Ipamorelin comes down to receptor biology. CJC-1295 works on the GHRH receptor, and Ipamorelin works on the ghrelin receptor. These are two distinct pathways that converge on the same target: your pituitary's somatotroph cells. When both receptors are activated simultaneously, the resulting GH pulse is larger than what either peptide produces alone.[4]

Think of it this way: CJC-1295 tells your pituitary "now is the time to release growth hormone," while Ipamorelin amplifies how much gets released during that window. Research on GHRH and ghrelin-mimetic co-administration has shown synergistic GH output, meaning the combined effect is greater than the sum of each peptide given individually.[4]

There is an important caveat here that most peptide content ignores: no controlled human trial has studied CJC-1295 and Ipamorelin specifically as a combined stack. The synergy rationale is built on studies of GHRH analogs combined with ghrelin mimetics more broadly, plus clinical observations from physicians prescribing this combination. It is a well-reasoned protocol with physiological support, but it is not the same as having a randomized controlled trial behind it.

The practical advantages of the stack include:

• Amplified GH output: Larger, stronger pulses than either peptide alone
• Preserved pulsatility: Your GH still comes in natural waves, avoiding the flat elevation of exogenous HGH
• Selective profile: Ipamorelin does not raise cortisol or prolactin, and CJC-1295 does not affect appetite, so the combination avoids common secretagogue side effects[3]
• Lower individual doses: Because the peptides work synergistically, you may need less of each to achieve meaningful GH elevation
• Flexible timing: The stack can be taken 1-3 times daily, with the pre-bed dose being the most important for aligning with your natural GH surge during deep sleep

Dosing Protocols

There is no FDA-approved dosing protocol for CJC-1295 or Ipamorelin in humans. The information below is compiled from clinical practice reports, prescribing physician protocols, and preclinical research. This is not a dosing recommendation.

Standard Doses

Timing Matters

The single most important dose is before bed, on an empty stomach. Growth hormone release peaks during deep sleep (stages 3 and 4 of non-REM sleep), and injecting 30-60 minutes before sleep amplifies that natural surge.[7] Food, particularly carbohydrates and fats, can blunt GH release by raising insulin, which directly opposes GH secretion. Aim for at least 90 minutes fasted before your injection.

If dosing multiple times daily, a common protocol is:

• Morning (fasted): 100 mcg CJC-1295 + 200 mcg Ipamorelin, upon waking before breakfast
• Pre-bed (fasted): 100 mcg CJC-1295 + 200 mcg Ipamorelin, 30-60 minutes before sleep
• Optional mid-day: Some protocols add a third dose post-workout or mid-afternoon, though this is less common

What to Expect: Timeline and Results

Setting realistic expectations matters. This is not exogenous HGH, and the effects build gradually as your body's own GH production increases over weeks. The timeline below is based on clinical observation reports and patient-reported outcomes, not controlled trials.

After managing my own GH optimization protocol for three years, including periods on this exact stack, I can confirm that the timeline above is realistic. The sleep benefits came first (within 10 days for me), and the body composition changes were gradual but measurable by week 8. The mistake most people make is expecting HGH-level results from a peptide that works through a fundamentally different mechanism. This stack optimizes what your body already does. It does not override it.

Side Effects and Safety

One of the main reasons clinicians favor the CJC-1295/Ipamorelin stack over direct HGH or older secretagogues is the side effect profile. Ipamorelin's selectivity for the GH pathway, without meaningfully affecting cortisol, prolactin, or appetite, gives it one of the cleanest profiles in the secretagogue class.[3]

Commonly Reported Side Effects

• Injection site reactions: Mild redness, itching, or a small welt at the injection site. This is the most frequently reported effect and typically resolves within 20-30 minutes
• Water retention: Mild fluid retention, particularly in the first 1-2 weeks. This is a known GH-related effect and usually self-corrects
• Head rush or lightheadedness: Some users report a brief wave of lightheadedness shortly after injection, lasting 1-5 minutes
• Increased hunger: Less common with Ipamorelin than with GHRP-6, but some people do notice a mild appetite increase
• Tingling or numbness in hands: Occasionally reported, and consistent with mild GH-related fluid shifts. If persistent, this may indicate the dose is too high

How This Compares to Exogenous HGH

Direct HGH injections at supraphysiological doses carry risks that this peptide stack largely avoids. Exogenous HGH can cause joint pain, carpal tunnel syndrome, insulin resistance, and (at very high doses) organ growth. The CJC-1295/Ipamorelin stack works within your body's natural feedback loops: your pituitary has a saturation point, and once it is reached, no additional GH gets released regardless of peptide dose.[9] That built-in ceiling is a meaningful safety advantage.

Long-Term Considerations

• Insulin sensitivity: Growth hormone opposes insulin action. Prolonged GH elevation, even through peptides, may affect blood glucose over time. Monitoring fasting glucose and HbA1c is important on any extended protocol[6]
• Pituitary feedback: There is limited data on whether long-term use affects your pituitary's natural GH output after discontinuation. Most clinical protocols run 3-6 month cycles with breaks
• Cancer risk: GH and IGF-1 promote cell growth. While no direct link between GH peptides and cancer initiation has been established, elevating growth factors in someone with pre-existing malignancy is a theoretical concern. Get screened appropriately before starting[5]

Who Is This Stack For?

Not everyone needs growth hormone peptides. If you are 25, sleeping 8 hours, training consistently, eating well, and recovering fine, your natural GH output is likely adequate and peptides offer marginal benefit at best. This stack has the most relevance for specific populations.

• Adults over 35-40 with documented low IGF-1: GH output declines approximately 14% per decade after age 30.[7] If your blood work shows IGF-1 in the lower quartile of the reference range for your age, this stack may be worth discussing with your physician
• People recovering from injuries: GH plays a role in tissue repair, collagen synthesis, and wound healing. Some recovery-focused peptide protocols incorporate this stack alongside peptides like BPC-157
• Those on TRT seeking complementary optimization: Testosterone and growth hormone work through different but overlapping pathways. Some TRT patients add this stack to address recovery, sleep, and body composition goals that testosterone alone may not fully cover
• Individuals focused on body composition who have plateaued: After optimizing nutrition, training, sleep, and stress management, this stack may help break through stubborn fat loss plateaus or support lean mass retention, particularly during caloric deficits

If you are exploring peptide stacking for the first time, our Peptide Stacks for Beginners guide covers how to approach combinations safely and what to monitor.

Frequently Asked Questions

How long does it take for CJC-1295 and Ipamorelin to work?

Most people notice the first effects (improved sleep quality, faster recovery) within 2-4 weeks. Measurable body composition changes typically appear at 6-8 weeks. Full protocol benefits, including fat loss and lean mass improvements, generally require 8-12 weeks of consistent use. Individual responses vary based on age, baseline GH levels, sleep quality, and overall health status.[8]

Can you take CJC-1295 and Ipamorelin without a prescription?

Regulations vary by country. In the United States, these peptides exist in a gray area. They are available through compounding pharmacies with a physician's prescription, and some are sold as "research chemicals" without prescriptions. The FDA has taken enforcement action against certain peptide sellers, and the regulatory landscape continues to shift. Working with a licensed physician who prescribes through a regulated compounding pharmacy is the safest and most legally clear path.[8]

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 without DAC (Mod GRF 1-29) has a short half-life (~30 minutes) and produces sharp GH pulses that mimic your natural rhythm. CJC-1295 with DAC has a half-life of 6-8 days and creates sustained GH elevation, which blunts the natural pulsatile pattern. Most clinicians who prescribe this stack prefer the non-DAC version because it preserves pulsatility and pairs better with Ipamorelin's own pulsatile mechanism.[1]

Is the CJC-1295/Ipamorelin stack safe long-term?

There are no long-term human studies on this specific combination. Clinical protocols typically run 3-6 months with breaks in between. The individual safety profiles of both peptides are favorable in available research, but the effects of sustained use over years remain unknown. Regular monitoring of IGF-1, blood glucose, and general health markers is standard practice for anyone on an extended protocol.[9] If your IGF-1 rises above the normal range, your prescribing physician should adjust the dose or cycle off.

The Bottom Line

The CJC-1295 and Ipamorelin stack is the most evidence-supported growth hormone peptide combination available. It works by amplifying your body's own GH production through two complementary receptor pathways, preserving the natural pulsatile release pattern that exogenous HGH overrides. The clinical data on each peptide individually is solid, though the combination itself has not been studied in a controlled human trial.

If you are considering this protocol, the non-negotiable steps are: get baseline blood work (especially IGF-1), work with a physician experienced in peptide therapy, source from a regulated compounding pharmacy, and monitor your labs throughout the cycle. This stack is a tool for optimization, not a substitute for the fundamentals of sleep, nutrition, training, and stress management.

• CJC-1295 + Ipamorelin amplifies your natural growth hormone pulses through two distinct receptor pathways
• The non-DAC form of CJC-1295 (Mod GRF 1-29) is preferred for stacking because it preserves pulsatile GH release
• Ipamorelin is the most selective GH secretagogue, avoiding the cortisol and prolactin spikes seen with older peptides
• Dosing is typically 100 mcg CJC-1295 + 200-300 mcg Ipamorelin, injected subcutaneously before bed on an empty stomach
• Sleep and recovery benefits appear within 2-4 weeks, body composition changes at 6-8 weeks
• No controlled human trial has studied this exact combination, though the physiological rationale is well-supported
• Monitor IGF-1, fasting glucose, and HbA1c throughout any GH peptide protocol

References

1. Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." J Clin Endocrinol Metab. 2006;91(3):799-805.
2. Nass R, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults." Ann Intern Med. 2008;149(9):601-611.
3. Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998;139(5):552-561.
4. Ionescu M, Bhatt DK. "Growth hormone-releasing hormone (GHRH) and its analogs." Endocr Rev. 2007;28(3):264-309.
5. Murphy WJ, Rui H, Longo DL. "Effects of growth hormone and prolactin on immune development and function." Life Sci. 1995;57(1):1-14.
6. Svensson J, et al. "Two-month treatment of obese subjects with the oral growth hormone secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure." J Clin Endocrinol Metab. 1998;83(2):362-369.
7. Veldhuis JD, et al. "Physiological attributes of healthy young adults vs. older men/women with decreased GH secretion." Int J Endocrinol. 2012.
8. PolitiFact. "What are peptides, and are they safe?" Published March 6, 2026.
9. UPMC HealthBeat. "What Is Peptide Therapy?" Published January 2026.